Policy & Regulation
CatalYm Closes EUR 50m Series C Financing
22 November 2022 - - Germany-based biotechnology company CatalYm has closed a EUR 50m (USD 49m) Series C financing round, the company said.

The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion.

The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.

Proceeds from the round will fund the expansion of CatalYm's visugromab Phase 2 development program.

This expansion is based on convincing efficacy and durability results in advanced, last-line patients in Phase 1 and continued positive clinical responses in the ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector cell Relocation Phase 2.

The study evaluates visugromab in combination with an anti-PD1 antibody in patients with advanced solid tumors that are relapsed/refractory to prior anti-PD1/-PD-L1 treatment and enrolls patients at clinical centers in Europe and the United States.

First data read-outs from the Phase 2 clinical trial program are expected to emerge in early 2023.

In conjunction with the close of the Series C financing, Dr. Jonathan Tobin, Partner at Brandon Capital and Dr. Andreas Wallnoefer, Partner at Jeito Capital will join CatalYm's board of directors.

CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment.

The company is pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors.

CatalYm's lead program visugromab is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment horizon for current and future immunotherapies.

Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment.

This enables the tumor to evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors.

Visugromab counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.

Brandon Capital is Australasia's leading life science venture capital firm, with an international presence and team members across the US and UK.

From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation.

Brandon BioCatalyst, Brandon Capital's Australasian-based collaboration, brings together 50 trans-Tasman medical research institutes, investors, and governments all united in progressing the next generation of medical therapies and technology.

Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries associated with member research organisations, providing both capital and expertise to guide the successful development of new therapies.

Jeito Capital is a global investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation.

Jeito Capital has EUR 534m under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
Login
Username:

Password:


Related Headlines